The global Cancer Biological Therapy Market is valued at USD 66.91 Billion in 2026.

The global Cancer Biological Therapy Market is experiencing steady growth as the demand for advanced and targeted cancer treatment approaches continues to increase. Biological therapies use substances derived from living organisms or biologically engineered products to treat cancer by stimulating the immune system, targeting specific cancer cells, blocking tumor growth, and improving the body’s ability to fight malignant diseases. Increasing cancer prevalence, advancements in biotechnology, rising investment in oncology research, and growing adoption of immunotherapy are supporting market expansion.

Market Overview

Cancer biological therapy refers to the use of biological substances and therapies to treat different types of cancer. These treatments include monoclonal antibodies, cancer vaccines, immune checkpoint inhibitors, cytokines, cell-based therapies, oncolytic virus therapies, and other biologically derived treatments.

Unlike conventional cancer treatments that primarily target rapidly dividing cells, biological therapies can work by stimulating the immune system, targeting specific molecules associated with cancer cells, or modifying biological processes involved in tumor development.

The increasing focus on personalized medicine, precision oncology, and advanced immunotherapy is encouraging healthcare providers to adopt biological treatment approaches. Continuous developments in genetic engineering, biotechnology, antibody-based treatments, and cellular immunotherapy are further expanding treatment possibilities across different cancer types.

Download Free Sample Report: https://brandessenceresearch.com/healthcare/cancer-biological-therapy-market#form

Growth Drivers & Trends

Several factors are supporting the growth of the Cancer Biological Therapy Market.

The rising global burden of cancer is one of the major factors driving demand for advanced biological treatments. Increasing diagnosis of breast cancer, lung cancer, colorectal cancer, prostate cancer, blood cancers, and other malignancies is encouraging healthcare organizations to explore innovative therapeutic approaches.

Growing adoption of immunotherapy is another important growth driver. Immune checkpoint inhibitors, monoclonal antibodies, and cellular immunotherapies are helping healthcare providers develop treatment strategies that activate or strengthen the body’s immune response against cancer cells.

Advancements in biotechnology and genetic engineering are also transforming the market. Innovations in antibody engineering, CAR T-cell therapy, bispecific antibodies, and personalized cancer vaccines are creating new opportunities for the development of advanced cancer treatments.

Another significant trend is the increasing focus on precision oncology. Biological therapies designed to target specific tumor biomarkers and molecular characteristics are supporting more personalized treatment approaches.

Additionally, increasing pharmaceutical research and development investments, strategic collaborations, and expanding clinical trial pipelines are contributing to the development of next-generation cancer biological therapies.

Market Segmentation

By Therapy Type

  • Monoclonal Antibodies
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Cytokines and Interferons
  • Adoptive Cell Therapy
  • CAR T-Cell Therapy
  • Oncolytic Virus Therapy
  • Other Biological Therapies

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Blood Cancer
  • Melanoma
  • Head and Neck Cancer
  • Other Cancers

By Treatment Approach

  • Immunotherapy
  • Targeted Biological Therapy
  • Cell-Based Therapy
  • Antibody-Based Therapy
  • Other Biological Treatment Approaches

By End User

  • Hospitals
  • Specialty Cancer Centers
  • Cancer Research Institutes
  • Academic and Research Institutions
  • Other Healthcare Facilities

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies

Regional Analysis

North America represents an important market for cancer biological therapies, supported by advanced healthcare infrastructure, strong pharmaceutical research and development capabilities, increasing adoption of immunotherapy, and the presence of leading biotechnology and pharmaceutical companies. The United States remains a significant contributor due to its established oncology treatment facilities, clinical research ecosystem, and availability of advanced biological medicines.

Europe is another prominent market, supported by increasing cancer awareness, government initiatives, established healthcare systems, and growing investments in biotechnology and cancer research. Countries such as Germany, the United Kingdom, France, Italy, and Spain are contributing to regional market development.

Asia Pacific is expected to offer significant growth opportunities as countries such as China, India, Japan, and South Korea continue to strengthen their healthcare infrastructure and expand access to advanced cancer treatments. Rising cancer incidence, increasing healthcare expenditure, growing pharmaceutical manufacturing capabilities, and expanding clinical research activities are supporting regional growth.

Latin America and the Middle East & Africa are also witnessing gradual market development, driven by improving oncology care facilities, increasing awareness, and growing access to innovative cancer treatment options.

Get the Complete Market Report – Buy Now   

Competitive Landscape

The global Cancer Biological Therapy Market is highly competitive, characterized by the presence of established pharmaceutical companies, biotechnology firms, and specialized oncology treatment developers.

Market participants are focusing on research and development, strategic collaborations, clinical trials, product innovation, and the expansion of biological therapy portfolios to strengthen their competitive positions.

Competition is primarily driven by advancements in immunotherapy, monoclonal antibody development, CAR T-cell technologies, personalized cancer treatments, clinical effectiveness, treatment safety, and regulatory approvals.

Key Players

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • Pfizer Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Sanofi
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals
  • GSK plc
  • Daiichi Sankyo Company, Limited
  • Takeda Pharmaceutical Company Limited
  • BeiGene
  • BioNTech SE
  • Genmab A/S
  • ImmunityBio, Inc.

Recent Developments

FDA – October 2026: The U.S. Food and Drug Administration approved atezolizumab (Tecentriq) in combination with chemotherapy for the adjuvant treatment of Stage III mismatch repair-deficient colon cancer, expanding the application of immunotherapy in cancer treatment.

FDA – August 2026: The FDA granted accelerated approval to vusolimogene oderparepvec (Tudriqev), a genetically modified oncolytic virus therapy, in combination with nivolumab for certain patients with advanced melanoma.

FDA – June 2026: The FDA approved an allogeneic regulatory T-cell-based immunotherapy for use in matched-donor hematopoietic stem cell transplantation for adults with hematologic malignancies.

FDA – May 2026: The FDA approved durvalumab (Imfinzi) in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer.

These developments highlight continued innovation in immune-based treatments, cellular therapies, and biologically engineered cancer treatments.

Frequently Asked Questions (FAQ)

  1. What is the projected market size and CAGR for the Cancer Biological Therapy Market?

The global Cancer Biological Therapy Market is valued at USD 66.91 Billion in 2026 and is expected to reach USD 92.26 Billion by 2032, growing at a CAGR of 5.5% over the forecast period.

  1. What are the major factors driving the growth of the Cancer Biological Therapy Market?

Key growth drivers include the increasing prevalence of cancer, rising adoption of immunotherapy, advancements in biotechnology, growing demand for personalized cancer treatments, increasing pharmaceutical research and development investments, and expanding availability of biological cancer therapies.

  1. What are the key technologies used in the Cancer Biological Therapy Market?

Major technologies include monoclonal antibody technology, immune checkpoint inhibition, CAR T-cell therapy, bispecific antibodies, cancer vaccine technology, cytokine-based treatments, oncolytic virus technology, genetic engineering, and cellular immunotherapy.

  1. Which are the major companies operating in the Cancer Biological Therapy Market?

Leading companies include Roche, Merck & Co., Bristol Myers Squibb, Novartis, Pfizer, Amgen, AstraZeneca, Johnson & Johnson, AbbVie, Gilead Sciences, Sanofi, Eli Lilly, Regeneron Pharmaceuticals, and GSK.

  1. What are the major segments of the Cancer Biological Therapy Market?

The market is commonly segmented by therapy type, application, treatment approach, end user, distribution channel, and geography.

Related Reports

About Us

At BrandEssence®, we help companies enhance their strategies by providing actionable insights. We use scientific research to investigate consumer views, perceptions, and expectations regarding an existing or proposed product or service launch. A variety of factors influence the success of a product and service launch, and scientific research helps organizations understand opinions, perceptions, and expectations.

The team at BrandEssence® applies market research methodologies across industries and domains, using research tools and analytical approaches to generate actionable market insights.

Contact Us

BrandEssence® Market Research and Consulting Pvt. Ltd.

Phone No.: +91 8975852287

Email Id: sales@brandessenceresearch.com

Website: https://brandessenceresearch.com/

    Written by

    Santosh Salgare

    Biographical InformationBrandEssence Market Research & Consulting Pvt. Ltd. is a Pune-based market research and consulting company focused on delivering high-quality market intelligence, primary research, and strategic advisory solutions to organizations across industries and geographies.Established with the objective of helping businesses make informed, evidence-based decisions, BrandEssence combines primary research, secondary research, industry expertise, data analytics, and strategic consulting to address complex business challenges.The company provides a broad range of services including market research reports, customized research, qualitative and quantitative research, competitive intelligence, market sizing and forecasting, sales intelligence, pricing analysis, market entry strategy, financial modelling, M&A consulting, and strategic advisory.BrandEssence has particular experience across Healthcare & Life Sciences, Pharmaceuticals, Biotechnology, Chemicals, Energy, Technology, Consumer Markets, Industrial sectors, and other emerging industries.A key strength of the organization is its emphasis on primary research and direct industry engagement. Its research teams engage with industry professionals, business leaders, subject-matter experts, customers, distributors, healthcare professionals, and other stakeholders to generate insights that go beyond publicly available information.Over the years, BrandEssence has worked with organizations ranging from corporates and research-driven businesses to government and institutional stakeholders, supporting them with market intelligence, opportunity assessment, strategic planning, and business growth initiatives.Today, BrandEssence is expanding beyond traditional market research into strategic consulting, country risk intelligence, macroeconomic analytics, financial modelling, and business advisory, with the aim of becoming a comprehensive intelligence and consulting partner for organizations operating in dynamic global markets.Headquarters: Pune, Maharashtra, India Industry: Market Research & Consulting Core Focus: Market Intelligence, Primary Research, Strategic Consulting & Business Advisory Geographic Coverage: India & Global Markets

    Leave a Comment